Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer Using Metabolon's Cellular Metabolism Tool

NEW YORK (GenomeWeb News) – Metabolon said today that Pfizer’s Bioprocess R&D Group is using the firm’s metabolomics technology in analyzing cellular metabolism in the biopharmaceutical production process.
 
Pfizer will use the biochemical profiling technology, called mVision, to analyze samples from bioreactors, said Research Triangle Park, NC-based Metabolon. The tool will enable researchers to identify essential nutrients that are depleted and unearth toxic metabolites in the cells.
 
“By monitoring a large number of biochemicals in a bioreactor process, customers can quickly uncover areas for optimization,” John Ryals, president and CEO of Metablon, said in a statement.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.